Abionyx Pharma SA
PAR:ABNX

Watchlist Manager
Abionyx Pharma SA Logo
Abionyx Pharma SA
PAR:ABNX
Watchlist
Price: 3.73 EUR -3.62% Market Closed
Market Cap: 130.3m EUR

Abionyx Pharma SA
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abionyx Pharma SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Abionyx Pharma SA
PAR:ABNX
Net Income (Common)
-€4.6m
CAGR 3-Years
8%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Net Income (Common)
-€85.5m
CAGR 3-Years
19%
CAGR 5-Years
-28%
CAGR 10-Years
-21%
Nanobiotix SA
PAR:NANO
Net Income (Common)
-€51.6m
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
-15%
Inventiva SA
PAR:IVA
Net Income (Common)
-€311.1m
CAGR 3-Years
-77%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Net Income (Common)
-$76.5m
CAGR 3-Years
24%
CAGR 5-Years
0%
CAGR 10-Years
-10%
DBV Technologies SA
PAR:DBV
Net Income (Common)
-$122.6m
CAGR 3-Years
-17%
CAGR 5-Years
14%
CAGR 10-Years
-16%
No Stocks Found

Abionyx Pharma SA
Glance View

Market Cap
129.7m EUR
Industry
Biotechnology

ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

ABNX Intrinsic Value
HIDDEN
Show

See Also

What is Abionyx Pharma SA's Net Income (Common)?
Net Income (Common)
-4.6m EUR

Based on the financial report for Jun 30, 2025, Abionyx Pharma SA's Net Income (Common) amounts to -4.6m EUR.

What is Abionyx Pharma SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-18%

Over the last year, the Net Income (Common) growth was -37%. The average annual Net Income (Common) growth rates for Abionyx Pharma SA have been 8% over the past three years , -18% over the past five years .

Back to Top